• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Chief Financial Officer Yuen Maggie sold $500,000 worth of shares (2,000 units at $250.00) and exercised 724 shares at a strike of $158.30, decreasing direct ownership by 9% to 13,667 units (SEC Form 4)

    8/15/25 7:49:54 PM ET
    $PEN
    Medical/Dental Instruments
    Health Care
    Get the next $PEN alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    X
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Yuen Maggie

    (Last) (First) (Middle)
    ONE PENUMBRA PLACE

    (Street)
    ALAMEDA CA 94502

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Penumbra Inc [ PEN ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Financial Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    08/13/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 08/13/2025 S(1) 2,000 D $250 12,943(2)(3) D
    Common Stock 08/15/2025 M 724 A $158.3 13,667(2)(3) D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (right to buy) $158.3 08/15/2025 M 724 (4) 12/15/2029 Common Stock 724 $0 5,376 D
    Explanation of Responses:
    1. The sales were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
    2. A portion of these shares is subject to vesting.
    3. Includes 86 shares purchased by the Reporting Person under the Issuer's Employee Stock Purchase Plan on May 19, 2025.
    4. All shares are vested and exercisable.
    Remarks:
    /s/ Stephen Dobson, as attorney-in-fact for Maggie Yuen 08/15/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $PEN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PEN

    DatePrice TargetRatingAnalyst
    3/14/2025$320.00Buy
    BofA Securities
    1/21/2025$305.00Buy
    UBS
    12/17/2024$275.00Outperform
    Oppenheimer
    12/11/2024$190.00 → $275.00Equal Weight → Overweight
    Wells Fargo
    9/18/2024$238.00Buy
    Stifel
    9/3/2024$263.00Outperform
    Leerink Partners
    7/31/2024$289.00 → $150.00Overweight → Equal Weight
    Wells Fargo
    7/31/2024$165.00 → $178.00Buy → Neutral
    Citigroup
    More analyst ratings

    $PEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BofA Securities initiated coverage on Penumbra with a new price target

    BofA Securities initiated coverage of Penumbra with a rating of Buy and set a new price target of $320.00

    3/14/25 7:46:38 AM ET
    $PEN
    Medical/Dental Instruments
    Health Care

    UBS initiated coverage on Penumbra with a new price target

    UBS initiated coverage of Penumbra with a rating of Buy and set a new price target of $305.00

    1/21/25 8:26:37 AM ET
    $PEN
    Medical/Dental Instruments
    Health Care

    Oppenheimer initiated coverage on Penumbra with a new price target

    Oppenheimer initiated coverage of Penumbra with a rating of Outperform and set a new price target of $275.00

    12/17/24 7:54:12 AM ET
    $PEN
    Medical/Dental Instruments
    Health Care

    $PEN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Penumbra, Inc. to Present at Upcoming Investor Conferences

    ALAMEDA, Calif., Aug. 20, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN) today announced that its management team is scheduled to present at the following investor conferences on the dates and times listed below. Event:  2025 Wells Fargo Healthcare Conference Date:  Wednesday, September 3, 2025 Time: 8:45am ET/5:45am PT Event: Morgan Stanley 23rd Annual Global Healthcare Conference Date:  Tuesday, September 9, 2025 Time:  1:50pm ET/10:50am PT Webcasts of the presentations can be accessed on the "Events and Presentations" section under the "Investors" tab of the company's

    8/20/25 4:30:00 PM ET
    $PEN
    Medical/Dental Instruments
    Health Care

    Penumbra, Inc. to Present at the Canaccord Genuity 45th Annual Growth Conference

    ALAMEDA, Calif., July 30, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN) today announced that its management team is scheduled to present at the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025. Event: Canaccord Genuity 45th Annual Growth Conference Date: Tuesday, August 12, 2025 Time: 12:30pm ET/9:30am PT A webcast of the presentation can be accessed on the "Events and Presentations" section under the "Investors" tab of the company's website at www.penumbrainc.com. The webcast will be available on the company's website for at least two weeks followi

    7/30/25 4:30:00 PM ET
    $PEN
    Medical/Dental Instruments
    Health Care

    Penumbra, Inc. Reports Second Quarter 2025 Financial Results

    ALAMEDA, Calif., July 29, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN), the world's leading thrombectomy company, today reported financial results for the second quarter ended June 30, 2025. Revenue of $339.5 million in the second quarter of 2025, an increase of 13.4% or 12.7% in constant currency1, compared to the second quarter of 2024.U.S. Thrombectomy revenue of $188.5 million in the second quarter of 2025, an increase of 22.6% compared to the second quarter of 2024. U.S. VTE revenue increased 42% compared to the same period a year ago.Income from operations of $40.8 mil

    7/29/25 4:05:00 PM ET
    $PEN
    Medical/Dental Instruments
    Health Care

    $PEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Yuen Maggie sold $500,000 worth of shares (2,000 units at $250.00) and exercised 724 shares at a strike of $158.30, decreasing direct ownership by 9% to 13,667 units (SEC Form 4)

    4 - Penumbra Inc (0001321732) (Issuer)

    8/15/25 7:49:54 PM ET
    $PEN
    Medical/Dental Instruments
    Health Care

    Director Bose Arani sold $3,007,776 worth of shares (12,000 units at $250.65), decreasing direct ownership by 96% to 558 units (SEC Form 4)

    4 - Penumbra Inc (0001321732) (Issuer)

    8/15/25 7:44:58 PM ET
    $PEN
    Medical/Dental Instruments
    Health Care

    Director Wilder Thomas sold $89,340 worth of shares (372 units at $240.16), decreasing direct ownership by 50% to 372 units (SEC Form 4)

    4 - Penumbra Inc (0001321732) (Issuer)

    8/13/25 7:44:47 PM ET
    $PEN
    Medical/Dental Instruments
    Health Care

    $PEN
    Leadership Updates

    Live Leadership Updates

    View All

    Get Out the Clot Campaign Brings Together Leaders and Experts to Improve Patient Care for Venous Thromboembolism

    Campaign is led by prominent medical societies to minimize discrepancies in treating blood clot conditions, such as in pulmonary embolism, where there are often delays in care (up to 26% of patients in one study) and misdiagnosis (up to 53% of patients in one study)1,2 ALAMEDA, Calif., Oct. 10, 2024 /PRNewswire/ -- The International Society on Thrombosis and Haemostasis (ISTH), National Blood Clot Alliance (NBCA), Penumbra, Inc. (NYSE:PEN), The PERT Consortium™ and Society for Vascular Medicine (SVM) today announced the launch of the Get Out the Clot campaign in advance of World Thrombosis Day on October 13. The campaign is a collaborative educational initiative focused on identifying gaps i

    10/10/24 9:00:00 AM ET
    $PEN
    Medical/Dental Instruments
    Health Care

    Omniscient Neurotechnology Appoints Two New Members to Its Board of Directors

    SYDNEY, Australia, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Omniscient Neurotechnology, the brain mapping company creating new possibilities in brain health, today announced the appointment of Barbara Nelson and Surbhi Sarna to its board of directors. Both appointees are visionaries across the biotech, healthcare and technology industries and bring a unique perspective to the company's corporate strategy and growth. They, along with the existing board members, will strategically guide Omniscient as it develops products that unlock new insights into advanced brain care. "Omniscient is a global leader in connectomics, but we have much work ahead of us to scale to our full potential," said Chairma

    10/24/22 8:30:00 AM ET
    $BLZE
    $GSIT
    $PEN
    Computer Software: Prepackaged Software
    Technology
    Semiconductors
    Medical/Dental Instruments

    $PEN
    Financials

    Live finance-specific insights

    View All

    Penumbra, Inc. Reports Second Quarter 2025 Financial Results

    ALAMEDA, Calif., July 29, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN), the world's leading thrombectomy company, today reported financial results for the second quarter ended June 30, 2025. Revenue of $339.5 million in the second quarter of 2025, an increase of 13.4% or 12.7% in constant currency1, compared to the second quarter of 2024.U.S. Thrombectomy revenue of $188.5 million in the second quarter of 2025, an increase of 22.6% compared to the second quarter of 2024. U.S. VTE revenue increased 42% compared to the same period a year ago.Income from operations of $40.8 mil

    7/29/25 4:05:00 PM ET
    $PEN
    Medical/Dental Instruments
    Health Care

    Penumbra, Inc. Schedules Second Quarter 2025 Earnings Release and Conference Call for July 29, 2025

    ALAMEDA, Calif., July 1, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN) today announced that it will host a conference call to discuss financial results for the second quarter 2025 after market close on Tuesday, July 29, 2025 at 4:30 PM Eastern Time. A press release with second quarter 2025 financial results will be issued after market close that day. Webcast & Conference Call InformationThe conference call can be accessed live over the phone by dialing (888) 596-4144 (conference id: 6572573), or the webcast can be accessed on the "Events and Presentations" section under the "

    7/1/25 4:30:00 PM ET
    $PEN
    Medical/Dental Instruments
    Health Care

    Penumbra, Inc. Reports First Quarter 2025 Financial Results

    ALAMEDA, Calif., April 23, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN), the world's leading thrombectomy company, today reported financial results for the first quarter ended March 31, 2025. Revenue of $324.1 million in the first quarter of 2025, an increase of 16.3% or 16.9% in constant currency1, compared to the first quarter of 2024.U.S. Thrombectomy revenue of $187.9 million in the first quarter of 2025, an increase of 25.0% compared to the first quarter of 2024.Income from operations of $40.4 million or operating margin of 12.4% in the first quarter of 2025.Net income

    4/23/25 4:05:00 PM ET
    $PEN
    Medical/Dental Instruments
    Health Care

    $PEN
    SEC Filings

    View All

    SEC Form 10-Q filed by Penumbra Inc.

    10-Q - Penumbra Inc (0001321732) (Filer)

    7/29/25 4:53:53 PM ET
    $PEN
    Medical/Dental Instruments
    Health Care

    Penumbra Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Penumbra Inc (0001321732) (Filer)

    7/29/25 4:14:41 PM ET
    $PEN
    Medical/Dental Instruments
    Health Care

    SEC Form SD filed by Penumbra Inc.

    SD - Penumbra Inc (0001321732) (Filer)

    5/30/25 4:20:01 PM ET
    $PEN
    Medical/Dental Instruments
    Health Care

    $PEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Penumbra Inc.

    SC 13G/A - Penumbra Inc (0001321732) (Subject)

    11/14/24 1:22:36 PM ET
    $PEN
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Penumbra Inc.

    SC 13G/A - Penumbra Inc (0001321732) (Subject)

    11/12/24 12:53:28 PM ET
    $PEN
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Penumbra Inc.

    SC 13G - Penumbra Inc (0001321732) (Subject)

    2/14/24 10:03:02 AM ET
    $PEN
    Medical/Dental Instruments
    Health Care